Search results for "Biosimilar Pharmaceuticals"

showing 6 items of 6 documents

Biosimilars and Novel Insulins.

2019

Background Insulin therapy is the mainstay of treatment for type 1 diabetes and may be necessary in type 2 diabetes. Current insulin analogues present a more physiological profile, are effective, and with less risk of hypoglycemia, but they are expensive. Biosimilar insulins should offer the advantages of insulin analogues at reduced costs. In addition, current rapid-acting insulin analogues are not fast enough to control excessive postprandial glucose excursions in many patients. Areas of uncertainty Biosimilar insulins demonstrated that are safe and effective, but interchangeability and automatic substitution remain an issue. Ultrafast-acting insulins should reduce postprandial hyperglyce…

Blood Glucosemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentInsulin GlargineType 2 diabetes030204 cardiovascular system & hematologyHypoglycemiaInsulin aspart03 medical and health sciences0302 clinical medicinemedicineInsulin lisproHumansHypoglycemic AgentsPharmacology (medical)030212 general & internal medicineIntensive care medicineBiosimilar PharmaceuticalsRandomized Controlled Trials as TopicPharmacologyGlycated HemoglobinType 1 diabetesInsulin Lisprobusiness.industryInsulin glargineInsulinnutritional and metabolic diseasesBiosimilarGeneral Medicinemedicine.diseaseDiabetes Mellitus Type 1Diabetes Mellitus Type 2Hyperglycemiabusinessmedicine.drugAmerican journal of therapeutics
researchProduct

Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes.

2022

Diabetes Mellitus Type 2Drugs GenericHumansHypoglycemic AgentsPharmacology (medical)General MedicineGeneral Pharmacology Toxicology and PharmaceuticsLiraglutideBiosimilar PharmaceuticalsGlucagon-Like Peptide-1 ReceptorBiosimilar GLP-1 diabetes generics liraglutide treatmentExpert review of clinical pharmacology
researchProduct

Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group

2022

Objective: The aim was to assess the awareness and real-life use of biosimilars in inflammatory bowel disease (IBD) among the members of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). Methods: An anonymous web survey involving all SIGENP IBD units which can prescribe biosimilars was conducted between July 1st and December 1st, 2020. The questionnaire included 18 questions addressing the most relevant aspects of biosimilars in pediatric IBD, i.e., advantages, disadvantages, costs, traceability, general knowledge, and real-life use. A descriptive analysis of responses was performed. Results: Responses came from 26 pediatric IBD units in Italy, with repre…

Inflammatory Bowel Diseasesbiosimilars; inflammatory bowel disease; childrendigestive system diseasesChild; Chronic Disease; Humans; Surveys and Questionnaires; Biosimilar Pharmaceuticals; Inflammatory Bowel DiseasesSurveys and QuestionnairesPediatrics Perinatology and Child HealthChronic DiseaseSurveys and QuestionnaireHumansPharmacology (medical)ChildBiosimilar PharmaceuticalsHumanBiosimilar Pharmaceutical
researchProduct

Ensuring the Consistency of Biosimilars

2017

Background: Biological products are subject to constant reappraisal by regulatory agencies and pharmaceutical companies once they have entered the market, since every improvement in their manufacturing process has the potential to alter the basic properties of these molecules. Methods: Narrative review focusing on scientific literature as well as legal documents from regulatory agencies. Results: Evaluating the impact of each manufacturing change of these drugs requires rigorous analyses in proportion to the anticipated risk of inducing more or less molecular micro-heterogenicity. There are currently more than 30 biosimilars of TNF-alpha blockers at different stages of testing, each with a …

Quality Controlmedia_common.quotation_subjectBiologíaScientific literature0603 philosophy ethics and religion03 medical and health sciencesPatient safety0302 clinical medicineConsistency (negotiation)Order (exchange)Drug DiscoveryHumansQuality (business)030212 general & internal medicineBiosimilar Pharmaceuticalsmedia_commonPharmacologyMedicamentoManufacturing processTumor Necrosis Factor-alphaBiosimilar06 humanities and the artsRisk analysis (engineering)Control de calidadMedicamentosNarrative review060301 applied ethicsBusinessCalidad
researchProduct

The new world of biosimilars: what diabetologists need to know about biosimilar insulins

2010

Biosimilar pharmaceuticals are emerging as patent protection on the original biopharmaceutical products expires. However, biopharmaceuticals are particularly complex molecules, and biosimilar insulins present special challenges. In part this reflects their structure and chemical modification after synthesis to attain a biologically active form. Their therapeutic window is narrow and the accuracy of their dosing is highly dependent on the formulation and quality of the administration device. For these reasons, the European Medicines Agency has issued stringent guidelines that must be fulfilled in order to receive approval as a biosimilar soluble insulin. Prescribers should therefore consider…

Therapeutic windowbusiness.industryEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectBiosimilarBiopharmaceuticalBiosimilar PharmaceuticalsRisk analysis (engineering)Need to knowSoluble insulinInternal MedicineMedicineQuality (business)Cardiology and Cardiovascular MedicinebusinessPatent systemmedia_commonThe British Journal of Diabetes & Vascular Disease
researchProduct

S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2.

2019

The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recomm…

medicine.medical_specialtyTuberculosisAdolescentMEDLINEDermatologyDiseaseDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisBiological Factors0302 clinical medicinePharmacotherapyQuality of life (healthcare)PsoriasismedicineHumansPsoriasisChildBiosimilar PharmaceuticalsTonsillectomybusiness.industryVaccinationmedicine.diseaseSkin CareAnti-Bacterial AgentsFamily medicineUltraviolet TherapyDermatologic AgentsbusinessGuttate psoriasisImmunosuppressive AgentsJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGReferences
researchProduct